Antibiotic resistance in Mycoplasma genitalium (MG) is rising globally, especially to macrolides. In response to this challenge, assays reporting both the detection of MG and macrolide resistance-mediating mutations (MRMM) allow therapy to be tailored to the individual. The study evaluated the performance of the ResistancePlus® MG FleXible assay for the detection of MG and MRMM. Overall, the test performed well for the detection of MG compared to the Allplex™ STI Essential assay, used as a reference, with a kappa value of 0.926 (95% CI, 0.863–0.990). The kit also performed well for the detection of MRMM when compared with Sanger sequencing of the 23S rRNA gene, with a kappa value of 0.901 (95% CI, 0.807–0.996). The rate of MRMM in MG among the study population was 41.8%. In conclusion, the ResistancePlus® MG FleXible is a rapid, simple and accurate cartridge-based assay for simultaneous detection of MG and MRMM in clinical settings.

生殖支原体中的抗生素耐药性（MG）在全球范围内呈上升趋势，尤其是对大环内酯类药物而言。为了应对这一挑战，报告检测到MG和大环内酯类药物介导的突变（MRMM）的检测方法使得治疗可以针对个体进行。该研究评估了用于检测MG和MRMM的ResistancePlus®MG FleXible分析的性能。总体而言，与用作参考的Allplex™STI Essential分析相比，该测试在检测MG方面表现良好，kappa值为0.926（95％CI，0.863–0.990）。与Sanger测序的23S rRNA基因相比，该试剂盒对MRMM的检测也表现良好，kappa值为0.901（95％CI，0.807-0.996）。研究人群中MG的MRMM率为41.8％。总之，ResistancePlus®MG FleXible是一种快速，